Loading organizations...
clinical-stage biotech develops biologic therapies for musculoskeletal diseases: osteoporosis and osteogenesis imperfecta.
Angitia Biopharmaceuticals is a clinical-stage biotechnology company discovering and developing biologic therapies for serious musculoskeletal diseases, operating with dual headquarters in Woodland Hills, California, and Guangzhou, China. The pre-revenue enterprise focuses on advancing proprietary therapeutics to address unmet medical needs in bone and joint conditions, specifically targeting osteoporosis, osteogenesis imperfecta, and spinal fusion. Operating with approximately 37 employees, the organization has secured $300 million in total venture capital funding to advance its clinical pipeline. This capitalization includes a $122 million Series B round and a $120 million Series C financing to support clinical trials for assets like the FDA orphan drug-designated AGA2115. The firm is backed by a syndicate of prominent institutional investors, including Bain Capital Life Sciences, OrbiMed, Janus Henderson, and Matrix Partners China. Angitia Biopharmaceuticals was founded in 2018 by Dr. Hua Zhu Ke.
Angitia Biopharmaceuticals has raised $336.0M across 4 funding rounds.
Angitia Biopharmaceuticals has raised $336.0M in total across 4 funding rounds.
Angitia Biopharmaceuticals has raised $336.0M in total across 4 funding rounds.
Angitia Biopharmaceuticals's investors include Frazier Life Sciences, Venrock, 3H Health Investment, Ascenta Capital, Bain Capital Life Sciences, BlackRock, BVF Partners, Elikon Venture, Hillhouse Capital Group, Janus Henderson Investors, Legend Capital, Logos Capital.
Angitia Biopharmaceuticals has raised $336.0M across 4 funding rounds. Most recently, it raised $130.0M Series D in February 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 5, 2026 | $130.0M Series D | Frazier Life Sciences, Venrock | 3H Health Investment, Ascenta Capital, Bain Capital Life Sciences, BlackRock, BVF Partners, Elikon Venture, Hillhouse Capital Group, Janus Henderson Investors, Legend Capital, Logos Capital, Morningside, OrbiMed, RA Capital Management, TF Capital, Yonghua Capital |
| Dec 11, 2024 | $120.0M Series C | Bain Capital Life Sciences | 3H Health Investment, Janus Henderson Investors, Legend Capital, OrbiMed, Yonghua Capital |
| Feb 28, 2024 | $40.0M Series B | Guangzhou High-tech Control, Zhuoyue (卓粤) Li (李) | |
| Oct 25, 2023 | $46.0M Series B Extension | Morningside Ventures | 3H Health Investment, Legend Capital, OrbiMed |